Gilead Sciences Inc said it has reached an agreement to acquire the Princeton, New Jersey-based Pharmasset Inc in order to accelerate the development of an all-oral compound for the treatment of HCV. The transaction is valued at $11 billion. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
